Aptar Pharma's preservative-free multi-dose ophthalmic squeeze dispense launched in the US
Courtesy of Aptar Pharma
First preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.
Aptar Pharma has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma’s innovative preservative-free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.
Following the worldwide trend towards safe, patient-friendly, cost-effective and preservative-free multi-dose dispensers such as Aptar Pharma's OSD system, the new over-the-counter (OTC) eye care product is able to maintain its status as the gold standard in lubricant eye drops.
The first OTC product marketed with OSD in the US
The newly released OTC eye drop product relieves dry, red, itchy eyes by providing preservative free eye drops in a revolutionary multi-dose bottle. Aptar Pharma has worked closely with a leading eye care company to improve patient safety, achieve dosing accuracy and maintain product integrity. The proprietary, sterile, lubricant eye drop formulation, contains 10 mL of solution, equivalent to more than 250 drops and claims to remain sterile for up to 3 months after first use. It is being supported by extensive television advertising and is available nationwide in pharmacies, supermarkets, and other retailers.
Meeting the needs of patients and consumers
Dry eye patients and consumers use lubricant eye drops on a regular basis, and often for the rest of their lives. It is well proven that preserved medications may cause unpleasant and sometimes serious side effects. Consequently, removing preservatives from the formulation by using Aptar Pharma’s OSD system is appreciated by the increasing number of patients and consumers experiencing eye irritation or allergic responses with preserved formulations.
Key benefits of Aptar Pharma’s OSD technology platform
Aptar Pharma’s OSD system is the result of more than 10 years of development for the delivery of preservative free ophthalmic solutions. European patients and consumers have benefited from this technology for years with more than 70 commercial references available on the market.
For the newly released over-the-counter product, Aptar Pharma’s OSD system delivers the following features:
· Unrivalled microbiological safety
· Intrinsic intuitiveness of a squeezable container
· User friendliness for all age groups due to a low actuation force
· Precise and reproducible drop ejection
· Ergonomic and pocket size design.
“The launch of Aptar Pharma’s OSD system in the US is a welcome event for patients suffering from eye irritations as it offers them significant benefits compared with standard therapy. This is also a very important milestone for Aptar Pharma in its international development strategy,” said Matthias Birkhoff, Vice President Business Development for Aptar Pharma’s Consumer Health Care Division.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.